Biovie (BIVI) traded up 7.26 % during a 24 hours period ending at 10:01 PM Central Europe on Tuesday 27th. One Biovie stock can currently be bought for about USD 1.44 on popular exchanges. Current supply of Biovie stocks is 7.5 mn. Biovie has a current market capitalization of USD 9.5 mn and approximately USD 184.9 k worth of Biovie was traded on exchanges in the last 24 hours. Since last month end, Biovie has traded -13.64 % down. Simple moving average of last 200 days is at USD 1.51. The highest price of past 52 weeks was recorded at USD 3.79 on 08/12/2026. 52 weeks low was at USD 0.82 on 08/06/2026.
Summary of the latest news for Biovie
BioVie Inc. has been invited to present data from its Phase 2 ADDRESS‑LC trial at the 2026 NIH RECOVER‑TLC workshop, where results on the investigational drug bezisterim for neurological symptoms of Long COVID will be discussed. The trial, focused on patients with fatigue, post‑exertional malaise, and cognitive impairment, reported a consistent trend of improvement across several patient‑reported and objective measures, with the most pronounced benefits seen in those with greater baseline symptom burden. Safety outcomes were comparable to placebo. The presentation aims to inform future research priorities and support the design of a confirmatory Phase 3 study. BioVie’s broader development program includes investigations of bezisterim in Parkinson’s disease and Alzheimer’s disease, with early data suggesting favorable biomarker and functional signals. The company continues to pursue regulatory‑grade trials and is advancing additional candidates for liver disease and neurodegenerative conditions.
Here is how related stocks have performed in the past 24 hours:
Curvebeam Ai (CVB.AX) traded down -4.76 % and now trades at AUD 0.02. Curvebeam Ai has a market capitalisation of AUD 16.1 mn. CurveBeam AI Limited has recently filed an initial director’s interest notice with the Australian Securities Exchange. The notice discloses that Daniel A. Pryor, who was appointed on 25 October 2026, holds a significant number of ordinary shares and share rights in the company. No other notable interests or contracts have been reported in the filing. The disclosure, made in compliance with listing rule 3.19A.1, provides the market with transparency regarding the director’s holdings but does not indicate any immediate changes to the company’s financial position or strategic direction.
Myndai (MYND) traded up 18.33 % and now trades at USD 0.32. Myndai has a market capitalisation of USD 11.3 mn.
Karyopharm Therapeutics (KPTI) traded down -6.95 % and now trades at USD 0.48. Karyopharm Therapeutics has a market capitalisation of USD 11.2 mn. Karyopharm Therapeutics Inc. has reported progress in its oncology pipeline following the release of a phase‑three trial of sacituzumab tirumotecan. The study, conducted across more than two hundred centres in 29 countries, demonstrated that the antibody‑drug conjugate significantly reduced tumour progression and death in women with recurrent endometrial cancer who had previously received immunotherapy. The company’s drug, which targets the Trop‑2 antigen on cancer cells, showed a higher tumour‑response rate compared with standard chemotherapy and produced manageable side effects such as low blood counts and oral mucositis. Karyopharm’s participation in the trial highlights its ongoing efforts to expand the use of sacituzumab tirumotecan beyond endometrial disease to other Trop‑2‑positive malignancies. The results are expected to influence future treatment guidelines for patients with advanced or relapsed endometrial cancer.
Citius (CTXR) traded up 11.41 % and now trades at USD 0.5. Citius has a market capitalisation of USD 11 mn. Citius Pharmaceuticals, Inc. filed a current report on 26 October 2026, announcing that its wholly‑owned subsidiary, Citius Oncology, released preliminary, unaudited sales figures for its approved therapy LYMPHIR in the fourth quarter of 2026. The report notes a substantial rise in unit sales to U.S. wholesalers—more than doubling since the prior quarter—and an increase in institutional vial orders. As of the release, 54 institutions had ordered the product, up from 44 in mid‑August. The company projects that the momentum built in the final quarter will carry into fiscal 2027, with continued growth in institutional demand and deeper market penetration. Full fiscal‑year results are expected in the December 2026 annual report.
Actuate Therapeutics (ACTU) traded up 11.16 % and now trades at USD 0.4. Actuate Therapeutics has a market capitalisation of USD 11.4 mn. Actuate Therapeutics, Inc. has filed a formal SEC EFFECT submission confirming the effective date of its S‑1 registration statement. The filing, recorded on October 26, 2026, updates the company’s public disclosure status under the 1933 Act and notes that the document is now live. The submission confirms the company’s name, formerly Apotheca Therapeutics, and provides its current address and contact details. No additional business or financial information is disclosed in this filing.
About Biovie
BioVie Inc. is a clinical stage biotechnology company based in the United States that is actively involved in uncovering, developing, and commercializing therapies directed towards life-threatening complications resulting from liver cirrhosis. Initial disease target of the company is ascites, a global health concern. BioVie’s Web address is https://bioviepharma.com/ , and they are traded on the Nasdaq stock exchange.